Editas Corp - EDIT Bozor kapitallashuvining balans qiymatiga nisbati
Editas Medicine, Inc. (EDIT) uchun xavflar patent nizolari, terapiyaning yuqori narxi va klinik sinovlarning potensial muvaffaqiyatsizliklari bilan bog'liq bo'lib, bu narxlar grafigida ko'rsatilganidek, metrika 3.90 qiymatida qotgan. Biznes qon va ko'rish patologiyalariga qarshi kurashish uchun CRISPR texnologiyalariga tayanadi. Yetakchi bioinformatiklarni jalb qiluvchi aksiyalar opsion dasturlari va noyob patentlar jamoaning barqarorligini ta'minlaydi.
%20Kapitallashuvning%20balans%20qiymatiga%20nisbati&width=1200&height=400&colorIndex=0&v=mvvwvvs9.gq-7b28iyo&start=20220704&end=20261031&filename=GURU_Markets_-_EDIT_-_Editas-Medicine-Inc._-_Capitalization-to-Book-Value-Ratio "EDIT: editasmedicine.com Bozor qiymatining balans qiymatiga nisbati 04.07.2022 - 31.10.2026 | 👁️GURU.Markets👁️")
Editas Medicine, Inc. kompaniyasining tahliliy kesimlari
- aksiya narxi va baholash bo'yicha konsensus prognoz:
- emitentning bozor qiymati haqida ma'lumotlar:
- buxgalteriya balansi bo'yicha sof aktivlar qiymati ko'rsatkichlari:
- qarzlar va to'lov qobiliyati haqida ma'lumot:
Umumiy qarzning kapitalga nisbati Editas Medicine, Inc.|EDIT - Uzoq muddatli majburiyatlarning kapitalga nisbati|Qisqa muddatli qarzning kapitalga nisbati Editas|EDIT - Kompaniyaning jamlangan qarzi|Balans kapitallashuviga qarzlar Editas|EDIT - Uzoq muddatli qarz hajmi|Kompaniyaning qisqa muddatli majburiyatlari Editas Medicine|Tezkor likvidlik koeffitsiyenti editasmedicine.com
- foyda va bozor multiplikatorlari tafsilotlari:
Kompaniyaning jamlanma tahlili:Editas Medicine, Inc. - EDIT
Ushbu ko'rsatkich sof balans qiymatidan yuqori bo'lgan bozor qiymati premiumini aks ettiradi va kotirovkalarning kompaniyaning haqiqiy aktivlariga nisbatan qanchalik shishirilganligini baholash imkonini beradi. CRISPR avtomatlashtirishi olimlarning qimmatbaho intellektual kapitaliga bo'lgan bog'liqlik bilan uyg'unlashgan Editas Medicine, Inc. (EDIT) uchun bozor-balans nisbati kelajakdagi kashfiyotlarga bo'lgan bozor kutganlarini aks ettirib, biznesning fundamental haddan tashqari baholanganligini belgilaydi.
Editas Medicine, Inc. (EDIT) raqobatchilari
TEM (Tempus Labs) - Kapitallashuvning sof aktivlarga nisbati|QGEN: Bozor kapitallashuvining balans qiymatiga multiplikatori|IONS (Ionis) - Bozor kapitallashuvining balans qiymatiga nisbati|Kapitallashuvning balans qiymatiga nisbati RGEN (Repligen Corp)|Bozor qiymatining balans qiymatiga nisbati Avidity (RNA)|CRISPR - Kapitallashuvning balans qiymatiga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati WGS (GeneDx Holdings Corp.)|Bozor kapitallashuvining balans qiymatiga nisbati ultragenyx.com RARE|Beam Therapeutics - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga koeffitsiyenti Sarepta Therapeutics|TWST: Bozor kapitallashuvining balans qiymatiga nisbati|Kapitallashuvning balans qiymatiga nisbati TXG|NTLA (Intellia Therapeutics) - Bozor kapitallashuvining balans qiymatiga nisbati|stoketherapeutics.com (STOK) - Balans qiymatiga nisbatan bozor kapitallashuvi|Kapitallashuvning sof aktivlarga nisbati BLFS (BioLife Solutions)|Bozor kapitallashuvining balans qiymatiga multiplikatori WVE|Bozor kapitallashuvining balans qiymatiga nisbati MAZE (Maze Tx)|Bozor kapitallashuvining balans qiymatiga nisbati Sionna Corp SION|PRME - Bozor qiymatining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor kapitallashuvi tayshagtx.com TSHA|QURE (uniQure) - Kapitallashuvning sof aktivlarga nisbati|MeiraGTx Holdings - Balans qiymatiga nisbatan bozor qiymati|Bozor qiymatining balans qiymatiga nisbati Regenxbio|Kapitallashuvning sof aktivlarga nisbati Solid Corp (SLDB)|Bozor kapitallashuvining balans qiymatiga nisbati OCGN|PACB - Bozor qiymatining balans qiymatiga koeffitsiyenti|Bozor kapitallashuvining balans qiymatiga nisbati BNTC (Benitec Biopharma)|DSGN: Kapitallashuvning balans qiymatiga nisbati|Rocket Pharmaceuticals Inc - Bozor kapitallashuvining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor kapitallashuvi 4D Molecular Corp FDMT|LXEO: Bozor kapitallashuvining balans qiymatiga nisbati|Kapitallashuvning sof aktivlarga nisbati Korro Bio|SLN (Silence Therapeutics plc) - Bozor kapitallashuvining balans qiymatiga nisbati|ProQR Therapeutics NV (PRQR) - Balans qiymatiga nisbatan bozor kapitallashuvi|Bozor qiymatining balans qiymatiga nisbati Codexis, Inc. (CDXS)|Sangamo BioSciences - Kapitallashuvning balans qiymatiga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati NAUT (Nautilus Bio)|metagenomi.co (MGX) - Bozor qiymatining balans qiymatiga koeffitsiyenti|DTIL: Kapitallashuvning sof aktivlarga nisbati|Balans qiymatiga nisbatan bozor qiymati GBIO (Generation Bio Co.)|BOLD: Bozor kapitallashuvining balans qiymatiga nisbati|XCUR - Balans qiymatiga nisbatan bozor kapitallashuvi|Bozor qiymatining balans qiymatiga nisbati Imunon Inc|Kapitallashuvning balans qiymatiga nisbati PHIO (RXi Pharmaceuticals)|Bozor kapitallashuvining balans qiymatiga nisbati MBIO|Kapitallashuvning sof aktivlarga nisbati transcodetherapeutics.com RNAZ|Bionano Genomics - Kapitallashuvning sof aktivlarga nisbati|Balans qiymatiga nisbatan bozor kapitallashuvi Applied DNA Corp (APDN)|bluebird bio, Inc. - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga koeffitsiyenti ImmunoPrecise Antibodies|OMGA: Bozor kapitallashuvining balans qiymatiga nisbati|Kapitallashuvning balans qiymatiga nisbati OMIC|RGLS (Regulus Therapeutics Inc) - Bozor kapitallashuvining balans qiymatiga nisbati|Syros Pharmaceuticals, Inc (SYRS) - Balans qiymatiga nisbatan bozor kapitallashuvi|Kapitallashuvning sof aktivlarga nisbati TBIO (Telesis Bio, Inc.)|Bozor kapitallashuvining balans qiymatiga multiplikatori TCON|Bozor kapitallashuvining balans qiymatiga nisbati UBX (Unity Biotechnology, Inc.)